

1 RUNNING TITLE: Stepwise endometriosis management

2

29 Tel. +3902.55032917; fax: +3902.55032818; electronic address: paolo.vercellini@unimi.it

30 CAPSULE

31 Two-thirds of symptomatic patients accepting a stepped-care endometriosis management were
32 satisfied with oral contraceptives and a low-cost progestin, and few had to step up to a high-cost
33 progestin or surgery.

34 ABSTRACT

35 **Objective:** To assess the proportion of patients with symptomatic endometriosis satisfied with their
36 medical treatment 12 months after enrollment in a stepped-care management protocol.

37 **Design:** Prospective, single-arm, self-controlled study.

38 **Setting:** Academic department.

39 **Patient(s):** A cohort of 157 consecutive patients referred or self-referred to our center for
40 symptomatic endometriosis.

41 **Intervention(s):** Systematic, detailed information process on medical and surgical treatment
42 followed by a shared decision to start a stepped-care protocol including three subsequent medical
43 therapy steps (oral contraception, [OC]; 2.5 mg/d norethindrone acetate, [NETA]; 2 mg/d dienogest,
44 [DNG]) and a fourth surgical step. Stepping up was triggered by drug inefficacy/intolerance.

45 **Main Outcome Measure (s):** Satisfaction with treatment was assessed according to a five-category
46 scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied).
47 Variation were measured in pain symptoms with the use of a 0-10 point numeric rating scale (NRS),
48 in quality of life with the use of Short Form-12 questionnaire (SF-12), and in sexual functioning
49 with the use of Female Sexual Function Index (FSFI).

50 **Result(s):** At the end of the 12-month study period, 106 women were still using OC, 23 were using
51 NETA, three were using DNG, and four had undergone surgery. Twenty-one (13%) participants
52 dropped out from the study. In intention-to-treat analysis, excluding five drop-outs for pregnancy
53 desire, the overall satisfaction rate with the stepped-care protocol was 62% (95/152; 95% CI, 55%
54 to 70%). By 12-month follow-up, significant improvements were observed in all pain symptoms
55 scores and in SF-12 physical and mental component summary scores, whereas FSFI scores did not
56 vary substantially.

57 **Conclusion(s):** Most women with endometriosis-associated pelvic pain who chose a stepped-care
58 approach, were satisfied with OC and a low-cost progestin for the treatment of their symptoms. The
59 need to step up to an expensive progestin or surgery was marginal.

60 KEYWORDS: endometriosis; pelvic pain; medical treatment; surgery.

61 INTRODUCTION

62 According to the opinion of the Practice Committee of the American Society for Reproductive
63 Medicine on treatment of endometriosis-associated pelvic pain, "*endometriosis should be viewed as*
64 *a chronic disease that requires a lifelong management plan with the goal of maximizing the use of*
65 *medical treatment and avoiding repeated surgical procedures*" (1).

66 In fact, surgery for endometriosis is reportedly effective for pelvic pain, but postoperative
67 recurrence of symptoms and lesions is as high as 40-50% at 5-year follow-up (2-4). Moreover,
68 removal of ovarian endometriomas is associated with reduction of ovarian reserve (5,6), and
69 excision of deep infiltrating forms is associated with a relatively high incidence of complications,
70 especially when rectovaginal and bowel lesions are present (3,7,8). Outcomes of complex surgical
71 procedures are strictly operator dependent and therefore scarcely reproducible. Finally, surgery is
72 expensive. For these reasons, many women would leave surgery as the second choice, only in case
73 medications are ineffective or not tolerated (9).

74 Based on secondary research findings (10) and according to guidelines issued by several
75 international gynecologic societies, hormonal compounds to treat endometriosis have similar effects
76 on pain, but different metabolic and subjective side-effects and costs (1, 11-14). Therefore, in
77 women who prefer medical rather than surgical treatment, those drugs with the most favorable
78 therapeutic profile and lower cost should be used first, stepping up to drugs with a less favorable
79 therapeutic profile or higher cost selectively in those patients who do not respond or do not tolerate
80 the first-line medications.

81 Despite decades of intensive clinical research, the ultimate prognosis of a woman with
82 symptomatic endometriosis who chooses prolonged medical treatment with first-line drugs instead
83 of surgery is currently unknown. In other words, the likelihood that a woman will succeed in
84 successfully controlling her complaints and be satisfied with her treatment without having to step-
85 up to second-line compounds and eventually to surgery is currently undefined. The answer to this
86 practical question seems crucial for informing patient decisions. Even women preferring medical

87 rather than surgical treatment may choose differently in case the risk of having to resort anyway to
88 surgery is high.

89 Given this unclear scenario, we deemed it of interest to assess the trajectory of an unselected
90 cohort of consecutive endometriosis patients through a pre-planned stepwise therapeutic protocol
91 including three subsequent medical steps (oral contraception, [OC]; norethindrone acetate,
92 [NETA]; dienogest, [DNG];) and a fourth, final, surgical step. The main objective of the
93 investigation was to estimate the probability of being satisfied with this stepped medical care
94 approach 1 year after starting the use of a low-dose OC.

95 MATERIALS AND METHODS

96 This study was conceived and designed, the results interpreted, and the report written, together with
97 representatives of a large Italian nonprofit endometriosis patient association (Associazione Progetto
98 Endometriosi Onlus), and it was conducted within the framework of a participatory research
99 initiative aimed at prioritizing topics and research questions that patients consider to be important.
100 Engaging patients in the design of a new pragmatic study model on endometriosis management was
101 deemed to be crucial to capturing aspects of health and functioning that matter to them.

102 The manuscript was prepared according to the Strengthening the Reporting of Observational
103 studies in Epidemiology guidelines for reporting observational studies (15). The investigation was
104 performed in an academic department specializing in endometriosis management, and the relevant
105 Institutional Review Board approved the study (Comitato di Etica Milano Area B, determination
106 no.903/2015). Every patient signed an informed consent form before enrollment.

107 **Design**

108 A prospective, single-arm, self-controlled, observational study design was adopted. The main
109 objective was to assess the degree of satisfaction with a stepped medical treatment care in a cohort
110 of consecutive patients with symptomatic endometriosis starting therapy with an OC used
111 continuously, and sequentially stepping up to NETA and then to DNG in case of drug inefficacy or
112 intolerance. Secondary objectives were the evaluation of within-person variations in pain

113 symptoms, health-related quality of life, and sexual function after 12 months, as well as of the
114 proportion of patients eventually needing to step up to surgery. With this study design each
115 participant acted as her own control, to avoid the potential confounding caused by differences
116 between patients (16). In fact, variations in satisfaction with treatment was not assessed after a pre-
117 planned shift to another drug in a general population of patients taking OC, but specifically in those
118 patients who stepped up to a second- or third-line medication owing to dissatisfaction with,
119 respectively, OC or NETA because of inefficacy or intolerability, and who would otherwise have
120 discontinued medical therapy.

121 **Study participants**

122 We considered 18- to 40-year-old women, not seeking conception, with a surgical diagnosis of
123 ovarian and/or deep endometriosis or a current nonsurgical diagnosis of ovarian and/or deep
124 endometriosis (17), consecutively referred or self-referred to our tertiary-care endometriosis center
125 because of moderate or severe pelvic pain symptoms of >6 months' duration. Those patients who
126 were already using any type of pharmacologic therapy and were satisfied with their treatment were
127 not considered for enrollment.

128 Nonsurgical diagnoses were based on ultrasonographic criteria in patients with ovarian
129 endometriomas (18,19); on visual inspection of the posterior fornix and biopsy of vaginal lesions in
130 those with rectovaginal endometriosis (20,21); on ultrasonographic criteria (22), cystoscopic
131 findings, and biopsy of vesical lesions in those with bladder detrusor endometriosis; on physical
132 signs at rectovaginal examination and ultrasonographic criteria (23,24) in those with deep lesions
133 infiltrating the Douglas pouch and parametria; and on ultrasonographic criteria (24), double-
134 contrast barium enema, and, in some women, rectosigmoidoscopy or colonoscopy findings in those
135 with full-thickness bowel lesions. Magnetic resonance imaging was performed in selected
136 circumstances. The ultrasonographic diagnosis of adenomyosis was based on detection of
137 asymmetric thickness of the anterior and posterior uterine walls, heterogeneous myometrial

138 echotexture, and round anechoic areas and hypoechoic linear striations within the myometrium
139 (25).

140 Patients were excluded in case of obstructive uropathy or subocclusive bowel stenosis,
141 evidence of complex adnexal cysts or a unilocular ovarian endometrioma with a diameter > 4 cm at
142 vaginal ultrasonography, the typical contraindications to OC and progestins, a diagnosis of
143 concomitant disorders that may cause pelvic pain independently of endometriosis presence (e.g.,
144 pelvic inflammatory disease or pelvic varices or genital malformations at previous surgery; known
145 urologic and orthopedic diseases), psychiatric disturbances, and history of drug or alcohol abuse.
146 From August 2015, all new endometriosis patients consecutively referred or self-referred to our
147 center were evaluated for eligibility, and recruiting continued until the pre-planned sample size was
148 reached in January 2016.

149 **The information process**

150 In our center, all women are thoroughly informed regarding the possible treatment options for their
151 clinical condition on the base of up-to-date literature evidence, with priority given to the best-
152 quality primary and secondary research available (26). The information is expressed quantitatively
153 with the use of absolute numbers (e.g., crude percentages with a consistent denominator, such as
154 100 treated), and avoiding the use of estimates that may not be easily understood (e.g., relative
155 risks), and it is provided in both verbal and written form. The communication session between the
156 physician and the patient has no predetermined time limits. Medical and surgical treatments are
157 described in detail and both are offered as available options.

158 Before deciding whether to start medical therapy or undergo surgery, women were informed
159 that OC is considered by some authors to be the first line treatment for endometriosis-associated
160 pelvic pain, but that further medical therapy steps are available in case of inefficacy or intolerance.
161 They were also informed that medical therapies for endometriosis are usually effective in reducing
162 various types of pain in about two thirds of patients (27-29). However, drugs induce only temporary
163 relief, are not expected to be definitively curative, and may cause several side effects (listed, with

164 percentages derived from previous studies conducted in our center). Finally, when hormonal
165 treatments are to be continued for long periods, estrogen-progestins and progestins appear to be
166 among the compounds that most favorably balance benefits, harms and costs (30,31). In particular,
167 the continuous use of OC is suggested to achieve amenorrhea and relieve pain at withdrawal
168 bleeding that may still afflict endometriosis patients using OC cyclically (32,33).

169 It was explained that the estrogen included in OC on one hand may prevent potentially
170 detrimental effects of hypoestrogenizing treatments (e.g., vaginal dryness, decrease in bone mineral
171 density, and unfavorable modifications in serum lipid pattern), but on the other hand may limit the
172 therapeutic efficacy on endometriotic implants that, being estrogen sensitive, may retain part of
173 their metabolic activity. Thus, in case of symptom persistence, a shift to a progestin monotherapy
174 may improve pain. This change of medication may be of benefit also in case of intolerance to OC,
175 because the estrogen component is generally associated with specific side-effects (e.g., headache)
176 (34). Differences in the effect on pain and in side-effects may exist even among different
177 progestins. Therefore, changing from NETA to DNG may relieve symptoms to a greater extent, or
178 untoward effects may subside. However, the likelihood and magnitude of these potential variations
179 are scarcely quantifiable owing to limited available evidence. Moreover, NETA is very cheap,
180 whereas DNG is costly.

181 Women were informed that other drugs for symptomatic endometriosis were available but
182 that, owing to important untoward effects and/or high costs, generally they were not suggested for
183 prolonged treatment periods. Finally, patients were also informed that laparoscopic surgery was a
184 reasonable alternative associated with a 70-80% probability of partial or complete pain relief in case
185 they declined medical therapy or switching from OC to a progestin, but that the risk of pain and
186 lesion recurrence was ~10% per year without long-term postoperative medical treatment (2-3), they
187 were also informed that, in case of excisional procedures for rectovaginal lesions, surgery is
188 associated with major complications in ~10% of cases (listed, with percentages derived from
189 published primary and secondary research). Finally, it was explained that repeat surgery, owing to

190 the presence of adhesions distorting abdominal-pelvic anatomy, may become less effective against
191 pain as well as riskier, although precise estimates may not be provided because of paucity of
192 published data.

193 **Interventions: the stepped care approach**

194 Women who chose medical therapy were invited to start a low-dose, monophasic OC used
195 continuously (Step 1). During the enrollment period, the OC used in our center was a monophasic
196 formulation containing 0.015 mg ethinyl-estradiol (EE) and 60 mg gestodene or, in case of spotting,
197 0.02 mg EE and 150 mg desogestrel. In smokers and in those with a body mass index (BMI) \geq 30
198 kg/m², a combination of 0.02 mg EE and 100 mg levonorgestrel was prescribed.

199 All patients underwent clinical and ultrasonographic evaluations at 3, 6, and 12 months after
200 enrollment, unless required otherwise because of pain recurrence or insurgence of untoward effects.
201 On these occasions, the women were asked to complete questionnaires on pain, quality of life, and
202 sexual functioning. They were also asked to indicate drug tolerability and to rate the degree of
203 overall satisfaction with their treatment. Whenever a participant was dissatisfied with OC because
204 of inefficacy for pain or intolerable side effects, she was counseled again and invited to consider
205 stepping up to NETA or undergoing surgery. Dissatisfied women who chose to continue with
206 medical treatment started NETA at the dose of 2.5 mg orally once a day, (Step 2), after 4 or 7 days
207 off OC, depending on the type being used. Norethindrone acetate, a 19-nortestosterone-derivative
208 progestin, has been repeatedly evaluated in women with endometriosis (35-41), and has been
209 successfully used in our referral center for several years (20,21,42).

210 When a participant was dissatisfied with NETA because of inefficacy for pain or intolerable
211 side-effects, she was counseled again and invited to consider stepping up to DNG or undergoing
212 surgery. Those women who chose to continue with medical treatment started DNG immediately at
213 the dose of 2 mg orally once a day, (Step 3). Dienogest, a semisynthetic 19-nortestosterone-
214 derivative progestin, has been investigated and registered also for the treatment of endometriosis. Its
215 effect on pain was demonstrated to be significantly superior to placebo and equivalent to a GnRH

216 analogue (43,44). Moreover, DNG was particularly well tolerated by women with symptomatic
217 endometriosis (43,44). Women were informed that DNG was indicated as step 3, instead of step 2,
218 because DNG is much more expensive than NETA and may have an adverse impact on bone
219 mineral density (43,45).

220 In case of prolonged spotting (≥ 7 days) or breakthrough bleeding, the patients were advised
221 to discontinue treatment for 1 week (4 days in case of OC containing 0.015 mg EE and 60 mg
222 gestodene). When needed, naproxen sodium was the standard nonsteroidal antiinflammatory drug
223 prescribed (one 550-mg tablet twice a day unless contraindicated).

224 When a participant was dissatisfied also with DNG because of inefficacy for pain or
225 intolerable side-effects, she was counseled again and invited to consider undergoing surgery (Step
226 4). However, surgery could be chosen by women also during OC or NETA use in case they
227 declined continuing with the stepped-care protocol. Laparoscopic treatment of endometriosis was
228 performed with mechanical and electrosurgical instrumentation according to standard and already
229 described techniques aiming at excising all endometriotic lesions and restoring a normal pelvic
230 anatomy (46-49). Participants who underwent surgery were regularly followed after the procedure.

231 **Measurements**

232 The presence and severity of dysmenorrhea, deep dyspareunia, nonmenstrual pelvic pain, and
233 dyschezia were assessed with the use of an 11-point numeric rating scale (NRS), with 0 indicating
234 absence of pain and 10 pain as bad as it could be. Patients were considered for enrollment if they
235 complained of at least one moderate-to-severe pain symptom (points 6-8, moderate pain; point 9 or
236 10, severe pain). Irregular bleeding during treatment was defined as spotting (scanty bleeding
237 requiring no more than one pad or tampon per day) or breakthrough bleeding (light or moderate
238 bleeding requiring two or more pads or tampons per day). Pain during spotting or breakthrough
239 bleeding was considered to be dysmenorrhea.

240 Quality of life was assessed with the use of the Short Form-12 (SF-12) health survey, a well-
241 known and validated self-administered 12-item instrument developed from the original SF-36

242 questionnaire (50,51). It measures health dimensions covering functional status, well-being, and
243 overall health. Information from the 12 items is used to construct physical and mental component
244 summary measures (52,53), with higher scores indicating better health perception.

245 The Female Sexual Function Index (FSFI) questionnaire is a 19-item, multidimensional,
246 self-report instrument for evaluating the main categories of female sexual dysfunction and sexual
247 satisfaction (54,55). Domains include desire, arousal, lubrication, orgasm, satisfaction, and pain.
248 Each domain is scored on a scale of 1 to 5, and the maximum transformed full-scale score is 36,
249 with a minimum transformed full-scale score of 2.0. Women with an FSFI total score <26.55 are
250 categorized as experiencing sexual dysfunction (56).

251 Patients rated the degree of satisfaction with their treatment according to a five-category
252 scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied) by
253 answering the following question: "Taking into consideration the variations occurring in pain
254 symptoms, overall physical and psychologic well-being, and sexual functioning, how would you
255 define the level of satisfaction with your current treatment?".

256 **Data management**

257 Based on our previous experience, the proportion of endometriosis patients satisfied with OC
258 treatment is ~ 65% (20,57). The study hypothesis was that the application of a stepwise treatment
259 approach, which includes the possibility of stepping up to NETA and then to DNG, could increase
260 this proportion to 80%. In our view, decreasing the dissatisfaction rate from one out of three to one
261 out of five women would be a clinically important difference. Based on the Wald method for a
262 binomial distribution, 150 participants were needed to limit the confidence interval (CI) around the
263 point estimate (80%) to 74%-86%.

264 Data were archived in Excel 2003 (Microsoft Corp.) and exported to SPSS 18.0, for
265 statistical analysis. Estimate of patient satisfaction rate was performed according to the intention-to-
266 treat principle, considering as dissatisfied all patients who dropped out of the study for any reason
267 except conception seeking, thus including request for not pre-planned medical therapies or need for

268 surgery, as well as loss to follow-up. To limit the potential effect of confounding, satisfaction with
269 treatment, was dichotomized into “satisfied” (very satisfied plus satisfied) and “dissatisfied”
270 (neither satisfied nor dissatisfied plus dissatisfied plus very dissatisfied).

271 Variations in pelvic pain symptoms, health-related quality of life, psychologic status, and
272 sexual functioning between baseline and 12-month values were evaluated by means of the paired
273 Student *t* test for normally distributed data (age, BMI, FSFI, SF-12), the non-parametric Wilcoxon
274 matched pairs test for nonnormally distributed data (NRS scores and number of days with
275 considerable pain or impairment of usual activity), the McNemar test for categoric variables, and
276 the Fisher Exact test in case of cells without numeric data. Per-protocol analyses were adopted for
277 secondary end points. Determinants of satisfaction with treatment were investigated with unpaired
278 tests (Student *t* test for normally distributed continuous variables, Wilcoxon test for nonnormally
279 distributed continuous variables, and chi-square test for categoric variables). The multivariate
280 analysis to evaluate the independent role of the variables predictive for satisfaction with treatment
281 was performed with the use of a logistic regression model. Specifically, those variables that were
282 found to significantly differ at univariate analysis were included in the model. All statistical tests
283 were two sided. A *P* value < .05 was considered to be statistically significant. When appropriate,
284 95% CIs were calculated for the observed differences by applying a binomial distribution model.

285

286 RESULTS

287 A total of 186 women were deemed to be eligible during the study period, but 29 (16%) declined
288 enrollment: 20 opted for cyclic OC use and nine for immediate surgery. The remaining 157 women
289 were recruited for the study (Fig. 1). The baseline demographic and clinical characteristics of the
290 patients are presented in Table 1. One-Half of the women previously underwent surgery for
291 endometriosis, and more than two-thirds previously used some medical therapies. A total of 64
292 patients (41%) had deep endometriotic lesions (rectovaginal, 56; other, 8), and 64 (41%) had
293 ovarian endometriomas (unilateral, 51, bilateral, 13). The median (interquartile range [IQR]) largest

294 deep lesion diameter was 15(10-20) mm (largest lesion diameter, 43 mm), and the median (IQR)
295 largest endometrioma diameter was 26 (19-38) mm (largest endometrioma diameter, 40 mm).
296 Thirty-three women (21%) had an ultrasonographic diagnosis of uterine adenomyosis
297 (Supplemental Table 1). No statistically significant differences were observed in baseline
298 characteristics between women who accepted and those who declined enrollment into the study
299 (data not shown).

300 **Participant progress through the stepped-care protocol**

301 Of the recruited 157 patients, 14 (9%) requested shifting to NETA (Step 2) within 3 months after
302 start of OC use (Step 1), because of inefficacy for pain ($n = 5$) or drug intolerance ($n = 9$), and one
303 requested surgery (Step 4) because of pain persistence. During the same time period, five
304 participants dropped out of the study (requested cyclic OC use because of intolerance to continuous
305 use, $n = 3$; declined further treatments, $n = 1$; lost to follow-up, $n = 1$; Fig. 1). At 6-month
306 assessment, 11 women had shifted from OC to NETA, and another two from NETA to DNG
307 because of inefficacy for pain ($n = 7$) or drug intolerance ($n = 6$). Two women taking OC underwent
308 surgery because of endometrioma growth. Seven patients dropped out between the 3- and 6-month
309 evaluations (declined further treatment, $n = 3$ (OC, $n = 2$; NETA, $n = 1$); requested cyclic instead of
310 continuous OC use, $n = 2$; pregnancy desire, $n = 2$ (OC, $n = 1$; NETA, $n = 1$)). Within the 12-month
311 assessment, six women shifted from OC to NETA and two from NETA to DNG, because of
312 inefficacy for pain ($n = 5$) or drug intolerance ($n = 3$) and one from DNG to surgery because of
313 inefficacy for pain. In the same time frame, nine patients dropped out of the study (pregnancy
314 desire, $n = 3$ (all OC); requested cyclic instead of continuous OC use, $n = 2$; declined further
315 treatments, $n = 2$ (OC, $n = 1$; NETA, $n = 1$); lost to follow-up, $n = 2$ (OC, $n = 1$; NETA, $n = 1$)).

316 At the end of the 12-month study period, 106 women were still using OC, 23 were using
317 NETA, three were using DNG, and four women had undergone surgery (including one who
318 requested surgery at the 12-month evaluation, after completion of the pre-planned 1-year medical
319 treatment period). Overall, 21 participants (13%) dropped out from the study, ten because of drug

320 intolerance (seven requested a shift from continuous to cyclic OC use and three declined further
321 treatments), five because of pregnancy desire, three because of psychologic intolerance to hormonal
322 therapies (they all declined further treatments), and three were lost to follow-up. The seven women
323 who requested to use OC cyclically instead of continuously, continued a medical treatment, but not
324 with the modality pre-planned for the stepwise protocol. For this reason, they were included among
325 dropouts.

326 **Pain symptoms, health-related quality of life, and sexual functioning**

327 A per-protocol analysis was conducted on the 133 women who completed the study (132 women
328 who continued medical treatment plus one who used medical treatment for 1 year and requested
329 surgery only at final 12-month evaluation). Highly statistically significant reductions in NRS score
330 were observed for all of the symptoms considered (Table 2). At the end of study period, the
331 prevalence of moderate or severe pain decreased from 94% to 12% for dysmenorrhea, from 59% to
332 30% for deep dyspareunia, from 43% to 12% for dyschezia, and from 44% to 23% for
333 nonmenstrual pelvic pain. The median (IQR) number of days with pain necessitating analgesics
334 decreased from 7(4-10) to 0(0-2) per month, and the number of days with impairment of usual
335 activities decreased from 2(0-4) to 0(0-0).

336 Significant improvements in summary scores for both; the physical (from 41.4 ± 11.1 to
337 51.0 ± 8.7) and the mental (from 41.9 ± 10.5 to 47.0 ± 10.0) SF-12 components were observed ($P <$
338 $.001$). A trend toward a marginal worsening of the FSFI score was observed (Table 2).

339 The incidence and types of untoward effects reported at pre-planned visits by women using
340 medical treatments are presented in Table 3. Side-effects were experienced by about four out of five
341 patients, but their severity determined drug discontinuation in only ten participants, seven of whom
342 requested shifting from continuous to cyclic OC use.

343 **Satisfaction with treatment**

344 At the 12-month assessment, 95 of the 133 participants who completed the stepwise protocol
345 were satisfied with their treatment (71%; 95% CI, 63%-79%). At the same time point, 38 women

346 declared that they were dissatisfied (OC, $n = 29$; NETA, $n = 8$; dienogest, $n = 1$), but only two of
347 them requested surgery. An intention-to-treat analysis was conducted on 152 patients, instead of the
348 157 enrolled, because five women dropped out of the study before the 12-month evaluation not
349 because of drug inefficacy or intolerance, but because of pregnancy desire. Considering all
350 remaining drop-outs and women who underwent surgery as dissatisfied, the overall satisfaction rate
351 was 62% (95/152; 95% CI, 55%-70%). However, seven drop-outs continued using OC, though
352 cyclically instead of continuously and six of them were satisfied with their treatment at 12-month
353 follow-up. Considering those seven women still under treatment would result in a less conservative,
354 but more realistic satisfaction rate of 66% (101/152; 95% CI, 59%-73%).

355 Baseline demographic and clinical characteristics of the 95 satisfied and 57 dissatisfied
356 patients in the intention-to-treat analysis, were substantially similar. In univariate analysis,
357 statistically significant differences were observed only for BMI and the SF-12 mental component
358 summary score, which were, slightly higher and lower, respectively, in the group of dissatisfied
359 women (Supplemental Table 2). In the logistic regression model, both BMI and the SF-12 mental
360 component summary score remained significantly associated with satisfaction with treatment ($P =$
361 .033 and .043, respectively).

362

363 DISCUSSION

364 According to the findings of this self-controlled study conducted prospectively on a cohort of
365 consecutive patients with symptomatic endometriosis who chose medical therapy as their preferred
366 treatment, the probability of stepping up to an expensive progestin (Step 3) because of intolerance
367 to NETA or to undergo surgery (Step 4) for any reason, was very limited. About two participants
368 out of three were satisfied with the proposed stepped medical care approach after 12 months. This
369 result was obtained with OC used continuously in the entire cohort of 157 women, NETA in 31
370 (20%), and DNG in four (3%). Surgery was needed in four women (3%), but in two of them the
371 indication was the unexpected growth of an ovarian endometrioma, not inefficacy of the drugs.

372 Unexpectedly, of the 38 women who declared themselves to be dissatisfied with medical
373 treatment, only two requested surgery, and the other 36 preferred to tolerate reduced but persistent
374 pain or some side-effects rather than undergo surgery. However, when pragmatically considering
375 the impact of medical treatment at large, also those 29 women who did not accept the stepped-care
376 protocol and requested cyclic OC use ($n = 20$) or immediate surgery ($n = 9$) should be considered.
377 Based on this conservative approach, surgery was eventually required in 13 ($4 + 9$) out of 186 (157
378 $+ 29$) patients (7%). Moreover, when planning the study, we hypothesized that 80% of women
379 would had been satisfied with the stepped-care medical approach, but this was not the case. In the
380 best scenario, that is, not excluding women who shifted from continuous to cyclic OC use, the
381 proportion of satisfied women was 66%, thus not superior to that repeatedly observed by us when
382 evaluating monotherapies. We recruited a series of consecutive women with endometriosis seeking
383 care for their pain symptoms, and what we have observed might provide an overall representation
384 of what unselected women can expect from medical treatment in the real world. These figures will
385 now be used in our practice when informing patients during the shared decision-making process,
386 specifying that the above estimates do not apply to the general population of women with
387 symptomatic endometriosis, but specifically to those women who choose medical rather than
388 surgical treatment.

389 We excluded women with endometriomas >4 cm. However, the maximum cyst diameter for
390 which surgery may be safely avoided in patients aged ≤ 40 years is currently undefined. Until a
391 consistent cutoff is indicated in guidelines issued by major scientific societies, the diameter of 5 cm
392 suggested by Muzii *et al.* (58) may be more appropriate in women with typical endometriomas.
393 Periodic evaluations are nevertheless recommended to detect in a timely manner possible
394 modifications of ultrasonographic cyst characteristics or unexpected growth during ovarian
395 suppression (58).

396 We deemed it to be important to describe in detail the information provided to patients, as
397 well as the standard shared decision-making process systematically adopted in our center, because a

398 strong relationship seems to exist between the characteristics of specific "centers of expertise"; and
399 the treatment chosen (i.e., medical or surgical) by patients referred to those centers. It may not be
400 excluded that the type of information provided largely determines the final patient decision
401 (26,59,60). According to Head *et al.* (61) "*certain details of alternate treatments can intentionally*
402 *or unintentionally be omitted, resulting in a failure to allow the patient to make a well informed*
403 *decision*". Therefore, in our view, the description of the information process should be included in
404 the methodologic section of future interventional trials for symptomatic endometriosis. In our
405 experience, when thoroughly informed on potential benefits, harms, and drawbacks of medical and
406 surgical treatments, most women not seeking conception express their preference for the former
407 option (21), thus confirming that patients who engage in shared decision-making tend to choose
408 nonsurgical treatment alternatives (62). Of relevance here, both medical and surgical treatments for
409 all endometriosis forms are available in our center and offered to patients.

410 The self-controlled design may appear to be a limitation of our study. However, this model
411 was chosen because our aim was not to conduct head-to-head comparisons between available
412 treatment options, but rather to evaluate sequentially the effect of different drugs used as a second-
413 or third-line therapy specifically in nonresponders to OC. In this setting, participants acted as their
414 own control, thus limiting the effect of confounding associated with different distribution among
415 patients of relevant characteristics that can influence study outcomes (16). Moreover, the adoption
416 of an intention-to-treat analysis to assess patient satisfaction, and including as dissatisfied all
417 participants who underwent surgery and all drop-outs except women who discontinued treatment to
418 seek a conception should have avoided overoptimistic results which are generally associated with
419 observational study designs.

420 Theoretically, the "regression toward the mean" phenomenon could have affected the
421 observed data, because extreme values are frequently influenced by random variation and; when
422 remeasured they tend to be closer to the mean of the original population from which the study
423 subjects were drawn (32,63). Therefore, when the patients' conditions are worse than average and

424 standard therapies seem to have lost efficacy, some general amelioration may occur that has nothing
425 to do with improved treatment (32,63). However, the magnitude of this effect should have been
426 limited here, because we recruited women complaining of chronic and fairly stable pain symptoms
427 that were measured on more than one occasion during the pre-enrollment phase and throughout the
428 study period (63). Also, a carry-over effect could not be excluded when stepping up because of drug
429 inefficacy or intolerance. However, in such a case the effect would have been negative and led to a
430 decrease in the patient satisfaction rate.

431 Selection bias could have influenced our findings, because choosing to enter the stepped-
432 care protocol in fact created a self-selection favoring hormonal therapy. This limits the
433 generalizability of our results to those women who prefer medical rather than surgical treatment. On
434 the other hand, recruiting consecutively all eligible patients referred to our center in a defined study
435 period should have limited these study drawbacks. Furthermore, the demographic and clinical
436 characteristics of women who accepted and refused entering the stepwise protocol were similar.

437 More in general, it may not be excluded that patients self-referring to our center are not
438 representative of the general population of women with endometriosis, because they may be more
439 prone to start medical therapies rather than request surgery. In fact, many patients may now easily
440 identify through the Internet and patient association websites those referral centers that are in favor
441 of medical treatment. However, this is a problem also for studies conducted in centers adopting
442 mainly a surgical approach. In addition, the attitude of the personnel of our center toward discussing
443 benefits and harms of all available treatment options, and the systematic application of a shared
444 decision-making process, may have had per se a psychologic effect, because women likely felt
445 understood and supported, although we did not measure such aspects. In theory, outcomes may vary
446 in centers applying different approaches regarding patient information and decision-making.
447 Nevertheless, a mere placebo effect, typically lasting no longer than a few weeks (64), seems
448 unlikely, given the relatively prolonged treatment period.

449 Health-related quality of life and sexual functioning were measured with the use of widely
450 used and reliable scales. The clinical validity and internal consistency of the SF-12 have been
451 demonstrated in large samples in many countries, including Italy (53,65). Both the physical and the
452 mental components of health-related quality of life, as measured by this instrument, were
453 substantially improved with the use of medical treatment.

454 The FSFI also has been validated and demonstrated acceptable internal consistency and test–
455 retest reliability (55,56). A marginal worsening of the FSFI scores from baseline to 12-month
456 assessment was observed. In our experience, significant improvements of sexual functioning as
457 measured by the FSFI were associated with progestin monotherapy (42,66). However, deep
458 dyspareunia persisted in ~30% of our patients. We speculate that OC, used by most of the study
459 participants, may exert a smaller effect on pain at intercourse owing to the estrogen component that
460 may impede complete metabolic inhibition of endometriotic foci (67). Moreover, it has been
461 demonstrated that OC may adversely affect desire, arousal, and pleasure (68).

462 The incidence of side effects of OC and progestins was surprisingly high. However,
463 occurrence of side-effects associated with medical treatments was actively investigated by research
464 fellows, and this may have lead (non è LED?) to listing even mild disturbances that otherwise
465 would not have been reported. Overall, untoward effects caused drug discontinuation in fewer than
466 one out of ~~10~~ ten patients, so most complaints were not severe enough to induce women to request
467 surgery.

468 Finally, representatives of a major national endometriosis patient association were
469 coinvestigators in this study. Partnership between patient associations and clinical investigators
470 seems to be important to move forward patient-centered research and ameliorate patient care.
471 Engaging patients for research on endometriosis management may help in defining those priorities
472 that are most important to them, at the same time advancing truly shared decision making (69-71).

473

474 CONCLUSIONS

475 The results of this prospective, self-controlled study suggest that most women with
476 symptomatic endometriosis were satisfied with OC and a low-cost progestin, and that only a small
477 minority of them actually needed a costly progestin or requested surgery to control pelvic pain.
478 Replication of our findings by other investigators is advisable, because the observed results may be
479 valid only for patients who prefer medical rather than surgical treatment, and may not be
480 generalizable to all patients with endometriosis.

481 In Italy, the yearly cost of treatment with the OC combinations used in our study is \$188-
482 197 / €159-167 / £146-154, with NETA is \$20 / €17 / £16, and with DNG is \$861 / €730 / £672.
483 Thus, the use of low-dose OC and low-cost progestins for endometriosis management may be
484 termed "high-value care" (72). The value of a medical intervention is the balance between its
485 potential benefits, potential harms, and costs, combined with the priorities and preferences of
486 individual patients. Value also conveys the dimension of the amount of care gained per each dollar
487 spent (72).

488 When correctly used in women without major contraindications, OC is very safe (73-76).
489 Thus, despite some limited drawbacks in terms of efficacy and tolerability (34,67), OC could retain
490 its role in the current therapeutic armamentarium for women with endometriosis (77,78). However,
491 those OC combinations with the lowest estrogen content (79-81) and associated with the smallest
492 amount of withdrawal bleeding (33) should be used and further investigated (77). Progestins may be
493 preferred in patients with deep infiltrating lesions (82).

494 According to the Institute of Medicine, clinical practice and research must be integrated to
495 define "*what work best for whom in order to inform decisions that lead to safe, efficient, effective,*
496 *and affordable care*" (83). The results of explanatory randomized controlled trials (RCTs) aimed at
497 defining the effect of experimental treatments may not be directly transferable to all patients,
498 because when treating a chronic disorder for years, the effect on pain is one among several factors
499 to be considered. Safety, tolerability, as well as costs for individual women and for the health care
500 system also should be taken into account. In other words, if a new drug has a demonstrated large

501 effect on pain, this does not mean that all patients with endometriosis should use that drug if its
502 safety and tolerability are no better than those of existing alternatives, but its cost is much higher. In
503 the words of Greenhalgh "*randomised controlled trials may constitute the ideal of experimental*
504 *design, but they alone can not prove that the right intervention has been provided to the right*
505 *patient at the right time and place*"(84). Moreover, patients encountered in everyday practice may
506 have different characteristics from those enrolled in explanatory RCTs.

507 The advent of new drugs for endometriosis (85-88) is very welcome, because this means
508 that patients will have another treatment option for managing their pain as an alternative to surgery.
509 Nevertheless, if new drugs are less safe or more expensive than existing ones, they should not be
510 prescribed to all women with symptomatic endometriosis, but solely in those who do not respond or
511 do not tolerate low-dose OC and low-cost progestins. Therefore, the evaluation of various stepwise
512 treatment protocols may be suggested with the objective of increasing the value of care for women
513 with endometriosis.

514

515

516

517

518

519

520

521

522

523

524 AUTHOR CONTRIBUTIONS

525 PV: conception and design of the study, interpretation of data, manuscript preparation; AD, FO, and
526 MPF: acquisition and analysis of data; AF, JF, and VN: conception and design of the study,

527 interpretation of data; AR and PM: analysis and interpretation of data; ED: design of the study,
528 analysis and interpretation of data; all the authors: critical revision of the article for important
529 intellectual content, and approval of the final version of the manuscript.

530

531 FUNDING

532 This study was financed by Italian fiscal contribution "5x1000" - Ministero dell'Istruzione,
533 dell'Università e della Ricerca - devolved to Fondazione Istituto di Ricovero e Cura a Carattere
534 Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

535

536 CONFLICT OF INTEREST

537 PV, AD, FO, AF, JF, VN, MPF, AR, and PM declare that they have no conflicts of interest. ES
538 received grants from Ferring and Serono.

539

540 ETHICAL APPROVAL

541 All procedures performed in this study were in accordance with the ethical standards of the local
542 institutional review board that approved the protocol on May 14, 2015 (Comitato Etico Milano Area
543 B, determination #903/2015)..

544 FIGURE LEGENDS

545 Figure 1. Flowchart showing recruitment and progress of participants through the study.

546

547 REFERENCES

- 548 1. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic
549 pain associated with endometriosis: a committee opinion. *Fertil Steril* 2014;101:927–35.
- 550 2. Guo SW. Recurrence of endometriosis and its control. *Hum Reprod Update* 2009;15:441–61.
- 551 3. Vercellini P, Crosignani PG, Abbiati A, Somigliana E, Viganò P, Fedele L. The effect of
552 surgery for symptomatic endometriosis: the other side of the story. *Hum Reprod Update*
553 2009;15:177–88.
- 554 4. Koga K, Takamura M, Fujii T, Osuga Y. Prevention of the recurrence of symptom and lesions
555 after conservative surgery for endometriosis. *Fertil Steril* 2015;104:793–801.
- 556 5. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian
557 reserve: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2012;97:3146–54.
- 558 6. Somigliana E, Berlanda N, Benaglia L, Viganò P, Vercellini P, Fedele L. Surgical excision of
559 endometriomas and ovarian reserve: a systematic review on serum antimüllerian hormone
560 level modifications. *Fertil Steril* 2012;98:1531–8.
- 561 7. De Cicco C, Corona R, Schonman R, Mailova K, Ussia A, Koninckx P. Bowel resection for
562 deep endometriosis: a systematic review. *BJOG* 2011;118:285–91.
- 563 8. Kondo W, Bourdel N, Tamburro S, Cavoli D, Jardon K, Rabischong B, et al. Complications
564 after surgery for deeply infiltrating pelvic endometriosis. *BJOG* 2011;118:292–8.
- 565 9. Vercellini P, Somigliana E, Cortinovis I, Bracco B, de Braud L, Dridi D, et al. “You can’t
566 always get what you want”: from doctrine to practicability of study designs for clinical
567 investigation in endometriosis. *BMC Womens Health* 2015;15:89.
- 568 10. Hickey M, Ballard K, Farquhar C. Endometriosis. *BMJ* 2014;348:g1752.
- 569 11. American College of Obstetricians and Gynecologists. Practice Bulletin No. 114: management
570 of endometriosis. *Obstet Gynecol* 2010;116:223–36.

- 571 12. Leyland N, Casper R, Laberge P, Singh SS, Society of Obstetricians and Gynaecologists of
572 Canada. Endometriosis: diagnosis and management. *J Obstet Gynaecol Canada* 2010;32:S1–
573 32.
- 574 13. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, et al.
575 ESHRE guideline: management of women with endometriosis. *Hum Reprod* 2014;29:400–12.
- 576 14. Kuznetsov L, Dworzynski K, Davies M, Overton C; Guideline Committee. Diagnosis and
577 management of endometriosis: summary of NICE guidance. *BMJ* 2017;358;j3935
- 578 15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The
579 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement:
580 guidelines for reporting observational studies. *PLoS Med* 2007;4:e296.
- 581 16. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver
582 injury: self controlled case series study in UK Clinical Practice Research Datalink. *BMJ*
583 2013;346:f1936.
- 584 17. Eskenazi B, Warner M, Bonsignore L, Olive D, Samuels S, Vercellini P. Validation study of
585 nonsurgical diagnosis of endometriosis. *Fertil Steril* 2001;76:929–35.
- 586 18. Moore J, Copley S, Morris J, Lindsell D, Golding S, Kennedy S. A systematic review of the
587 accuracy of ultrasound in the diagnosis of endometriosis. *Ultrasound Obstet. Gynecol.*
588 2002;20:630–4.
- 589 19. Van Holsbeke C, Van Calster B, Guerriero S, Savelli L, Paladini D, Lissoni AA, et al.
590 Endometriomas: their ultrasound characteristics. *Ultrasound Obstet Gynecol* 2010;35:730–40.
- 591 20. Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of
592 symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus
593 low-dose norethindrone acetate. *Fertil Steril* 2005;84:1375–87.
- 594 21. Vercellini P, Somigliana E, Consonni D, Frattaruolo MP, De Giorgi O, Fedele L. Surgical
595 versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on
596 pain during intercourse and patient satisfaction. *Hum Reprod* 2012;27:3450–9.

- 597 22. Savelli L, Manuzzi L, Pollastri P, Mabrouk M, Seracchioli R, Venturoli S. Diagnostic
598 accuracy and potential limitations of transvaginal sonography for bladder endometriosis.
599 *Ultrasound Obstet Gynecol* 2009;34:595–600.
- 600 23. Piketty M, Chopin N, Dousset B, Millischer-Bellaische AE, Roseau G, Leconte M, et al.
601 Preoperative work-up for patients with deeply infiltrating endometriosis: transvaginal
602 ultrasonography must definitely be the first-line imaging examination. *Hum Reprod*
603 2009;24:602–7.
- 604 24. Hudelist G, English J, Thomas AE, Tinelli A, Singer CF, Keckstein J. Diagnostic accuracy of
605 transvaginal ultrasound for non-invasive diagnosis of bowel endometriosis: systematic review
606 and meta-analysis. *Ultrasound Obstet Gynecol* 2011;37:257–63.
- 607 25. Benaglia L, Cardellicchio L, Leonardi M, Faulisi S, Vercellini P, Paffoni A, et al.
608 Asymptomatic adenomyosis and embryo implantation in IVF cycles. *Reprod Biomed Online*.
609 2014;29:606-11
- 610 26. Murad MH, Montori VM, Ioannidis JP, Jaeschke R, Devereaux PJ, Prasad K, et al. How to
611 read a systematic review and meta-analysis and apply the results to patient care: users' guides
612 to the medical literature. *JAMA* 2014;312:171–9.
- 613 27. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone
614 acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic
615 pain after conservative surgery for symptomatic endometriosis. *Fertil Steril* 2002;77:52–61.
- 616 28. Somigliana E, Viganò P, Barbara G, Vercellini P. Treatment of endometriosis-related pain:
617 options and outcomes. *Front Biosci (Elite Ed)* 2009;1:455–65.
- 618 29. Vercellini P, Somigliana E, Viganò P, Abbiati A, Barbara G, Crosignani PG. Endometriosis:
619 current therapies and new pharmacological developments. *Drugs* 2009;69:649–75.
- 620 30. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG.
621 Progestogens for endometriosis: forward to the past. *Hum Reprod Update* 2003;9:387–96.

- 622 31. Vercellini P, Crosignani P, Somigliana E, Viganò P, Frattaruolo MP, Fedele L. ‘Waiting for
623 Godot’: a commonsense approach to the medical treatment of endometriosis. *Hum Reprod*
624 2011;26:3–13.
- 625 32. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous
626 use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does
627 not respond to a cyclic pill regimen. *Fertil Steril* 2003;80:560–3.
- 628 33. Laux-Biehlmann A, d’Hooghe T, Zollner TM. Menstruation pulls the trigger for inflammation
629 and pain in endometriosis. *Trends Pharmacol Sci* 2015;36:270–6.
- 630 34. Morotti M, Remorgida V, Venturini PL, Ferrero S. Progestogen-only contraceptive pill
631 compared with combined oral contraceptive in the treatment of pain symptoms caused by
632 endometriosis in patients with migraine without aura. *Eur J Obstet Gynecol Reprod Biol*
633 2014;179:63–8.
- 634 35. Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of
635 symptomatic endometriosis. *Int J Fertil Womens Med* 1998;43:24–7.
- 636 36. Muneyyirci-Delale O, Jalou S, Rahman M, Nacharaju V. Can we decrease breakthrough
637 bleeding in patients with endometriosis on norethindrone acetate? *Int J Fertil Womens Med*
638 2003;48:32–6.
- 639 37. Ferrero S, Camerini G, Seracchioli R, Ragni N, Venturini PL, Remorgida V. Letrozole
640 combined with norethisterone acetate compared with norethisterone acetate alone in the
641 treatment of pain symptoms caused by endometriosis. *Hum Reprod* 2009;24:3033–41.
- 642 38. Ferrero S, Camerini G, Ragni N, Venturini PL, Biscaldi E, Remorgida V. Norethisterone
643 acetate in the treatment of colorectal endometriosis: a pilot study. *Hum Reprod* 2010;25:94–
644 100.
- 645 39. Kaser DJ, Missmer SA, Berry KF, Laufer MR. Use of norethindrone acetate alone for
646 postoperative suppression of endometriosis symptoms. *J Pediatr Adolesc Gynecol*
647 2012;25:105–8.

- 648 40. Muneyyirci-Delale O, Anopa J, Charles C, Mathur D, Parris R, Cutler JB, et al. Medical
649 management of recurrent endometrioma with long-term norethindrone acetate. *Int J Womens*
650 *Health* 2012;4:149–54.
- 651 41. Ferrero S, Remorgida V, Venturini PL, Leone Roberti Maggiore U. Norethisterone acetate
652 versus norethisterone acetate combined with letrozole for the treatment of ovarian
653 endometriotic cysts: a patient preference study. *Eur J Obstet Gynecol Reprod Biol*
654 2014;174:117–22.
- 655 42. Vercellini P, Frattaruolo MP, Somigliana E, Jones GL, Consonni D, Alberico D, et al.
656 Surgical versus low-dose progestin treatment for endometriosis-associated severe deep
657 dyspareunia II: effect on sexual functioning, psychological status and health-related quality of
658 life. *Hum Reprod* 2013;28:1221–30.
- 659 43. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as
660 leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized,
661 multicentre, open-label trial. *Hum Reprod* 2010;25:633–41.
- 662 44. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-
663 associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. *Eur J*
664 *Obstet Gynecol Reprod Biol* 2010;151:193–8.
- 665 45. Momoeda M, Harada T, Terakawa N, Aso T, Fukunaga M, Hagino H, et al. Long-term use of
666 dienogest for the treatment of endometriosis. *J Obstet Gynaecol Res* 2009;35:1069–76.
- 667 46. Vercellini P, Trespidi L, De Giorgi O, Cortesi I, Parazzini F, Crosignani PG. Endometriosis
668 and pelvic pain: relation to disease stage and localization. *Fertil Steril* 1996;65:299–304.
- 669 47. Vercellini P, Pietropaolo G, De Giorgi O, Daguati R, Pasin R, Crosignani PG. Reproductive
670 performance in infertile women with rectovaginal endometriosis: is surgery worthwhile? *Am J*
671 *Obstet Gynecol* 2006;195:1303–10.
- 672 48. Vercellini P, Carmignani L, Rubino T, Barbara G, Abbiati A, Fedele L. Surgery for deep
673 endometriosis: a pathogenesis-oriented approach. *Gynecol Obstet Invest* 2009;68:88–103.

- 674 49. Vercellini P, Parazzini F, Pietropaolo G, Cipriani S, Frattaruolo MP, Fedele L. Pregnancy
675 outcome in women with peritoneal, ovarian and rectovaginal endometriosis: a retrospective
676 cohort study. *BJOG* 2012;119:1538–43.
- 677 50. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
678 Conceptual framework and item selection. *Med Care* 1992;30:473–83.
- 679 51. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-
680 36): II. Psychometric and clinical tests of validity in measuring physical and mental health
681 constructs. *Med Care* 1999;31:247–63.
- 682 52. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of
683 scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220–33.
- 684 53. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation
685 of item selection and scoring for the SF-12 Health Survey in nine countries: results from the
686 IQOLA Project. *International Quality of Life Assessment J Clin Epidemiol* 1998;51:1171–8.
- 687 54. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual
688 Function Index (FSFI): a multidimensional self-report instrument for the assessment of female
689 sexual function. *J Sex Marital Ther* 2000;26:191–208.
- 690 55. Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female
691 orgasmic disorder and in women with hypoactive sexual desire disorder. *J Sex Marital Ther*
692 2003;29:39–46.
- 693 56. Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): cross-validation
694 and development of clinical cutoff scores. *J Sex Marital Ther* 2005;31:1–20.
- 695 57. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. A
696 gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain
697 associated with endometriosis. *Fertil Steril* 1993;60:75–9.
- 698 58. Muzii L, Tucci CD, Felicianantonio MD, Galati G, Verrelli L, Donato VD, et al. Management of
699 Endometriomas. *Semin Reprod Med.* 2017;35:25-30.

- 700 59. Berlanda N, Somigliana E, Frattaruolo MP, Buggio L, Dridi D, Vercellini P. Surgery versus
701 hormonal therapy for deep endometriosis: is it a choice of the physician? *Eur J Obstet*
702 *Gynecol Reprod Biol* 2017;209:67–71.
- 703 60. Soriano D, Jerome B. Should we also work on an international informed consent for
704 endometriosis surgery? *Hum Reprod* 2017;32:480.
- 705 61. Head SJ, Bogers AJ, Serruys PW, Takkenberg JJ, Kappetein AP. A crucial factor in shared
706 decision making: the team approach. *Lancet* 2011;377:1836.
- 707 62. Spatz ES, Krumholz HM, Moulton BW. Prime time for shared decision making. *Jama*
708 2017;317:1309-1310.
- 709 63. Louis TA, Lavori PW, Bailar JC III PM. Crossover and self-controlled designs in clinical
710 research. In: Bailar JC III, Mosteller F (eds). *Medical use of statistics*. Waltham, MA: NEJM
711 Books. 1986. p. 67–90.
- 712 64. Fedele L, Marchini M, Acaia B, Garagiola U, Tiengo M. Dynamics and significance of
713 placebo response in primary dysmenorrhea. *Pain* 1989;36:43–7.
- 714 65. Kodraliu G, Mosconi P, Groth N, Carmosino G, Perilli A, Gianicolo EA, et al. Subjective
715 health status assessment: evaluation of the Italian version of the SF-12 health survey. Results
716 from the MiOS project. *J Epidemiol Biostat* 2001;6:305–16.
- 717 66. Vercellini P, Bracco B, Mosconi P, Roberto A, Alberico D, Dhouha D, et al. Norethindrone
718 acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study.
719 *Fertil Steril* 2016;105:734–743.e3.
- 720 67. Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than
721 combined estrogen-progestin contraceptive pills. *Fertil Steril* 2017;107:533–6.
- 722 68. Zethraeus N, Dreber A, Ranehill E, Blomberg L, Labrie F, von Schoultz B, et al. Combined
723 Oral Contraceptives and Sexual Function in Women-a Double-Blind, Randomized, Placebo-
724 Controlled Trial. *J Clin Endocrinol Metab*. 2016:4046-4053.

- 726 69. Dancet EA, Ameye L, Sermeus W, Welkenhuysen M, Nelen WL, Tully L, et al. The
727 ENDOCARE questionnaire (ECQ): a valid and reliable instrument to measure the patient-
728 centeredness of endometriosis care in Europe. *Hum Reprod* 2011;26:2988–99.
- 729 70. Dancet EA, Apers S, Kremer JA, Nelen WL, Sermeus W, D’Hooghe TM. The patient-
730 centeredness of endometriosis care and targets for improvement: a systematic review. *Gynecol*
731 *Obstet Invest* 2014;78:69–80.
- 732 71. Horne AW, Saunders PTK, Abokhrais IM, Hogg L. Top ten endometriosis research priorities
733 in the UK and Ireland. *Lancet* 2017;389:2191–2.
- 734 72. Vercellini P, Giudice LC, Evers JL, Abrao MS. Reducing low-value care in endometriosis
735 between limited evidence and unresolved issues: a proposal. *Hum Reprod* 2015;30:1996–
736 2004.
- 737 73. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among
738 contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral
739 Contraception Study. *BMJ* 2010;340:c927.
- 740 74. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special
741 reference to oral contraceptive use. *Contraception* 2010;82:221–9.
- 742 75. Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family
743 Planning Association contraceptive study. *Contraception* 2013;88:678–83.
- 744 76. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and
745 combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception
746 Study. *Am J Obstet Gynecol* 2017;216:580.e1-580.e9.
- 747 77. Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S. Estrogen-progestins
748 and progestins for the management of endometriosis. *Fertil Steril* 2016;106:1552–1571.e2.
- 749 78. Harada T, Kosaka S, Elliesen J, Yasuda M, Ito M, Momoeda M. Ethinylestradiol 20
750 µg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-
751 associated pelvic pain: a randomized controlled trial. *Fertil Steril*. In press.

- 752 79. Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral
753 contraceptives: the risk of myocardial infarction and ischemic stroke. *Cochrane Database Syst*
754 *Rev* 2015:CD011054.
- 755 80. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen
756 T, et al. Combined oral contraceptives: venous thrombosis. *Cochrane Database Syst Rev*
757 2014:CD010813.
- 758 81. Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière PO, Rudant J, et al. Low dose
759 oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and
760 myocardial infarction in five million French women: cohort study. *BMJ* 2016;353:i2002
- 761 82. Vercellini P, Viganò P, Buggio L, Somigliana E. "We can work it out" the hundred years' war
762 between experts of surgical and medical treatment for symptomatic deep endometriosis. *J*
763 *Minim Invasive Gynecol* 2017. In press.
- 764 83. IOM Roundtable on value & science-driven care, institute of medicine. Integrating research
765 and practice: health system leaders working toward high-value care: workshop summary.
766 Washington (DC): National Academies Press (US).
- 767 84. Greenhalgh T. "Is my practice evidence-based?" *BMJ* 1996;313:957–8.
- 768 85. Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical
769 treatment of endometriosis: a systematic review. *Fertil Steril* 2017;108:125–36.
- 770 86. Bedaiwy MA, Allaire C, Alfaraj S. Long-term medical management of endometriosis with
771 dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy.
772 *Fertil Steril* 2017;107:537–48.
- 773 87. Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of
774 endometriosis-associated pain with elagolix, an oral GnRH antagonist. *N Engl J Med*
775 2017;377:28–40.
- 776 88. Taylor HS. Clinical diagnosis of endometriosis and optimal medical therapy. *Fertil Steril*. In
777 press

Table 1. Baseline demographic and clinical characteristics of the 157 women enrolled in the study.

Characteristic	Data
Age (y)	32.9 ± 5.7
Age (y) at first diagnosis	27.4 ± 5.4
BMI (kg/m ²)	21.6 ± 3.5
Previous deliveries	34 (22)
Previous interventions for endometriosis	
None	78 (50)
1	58 (37)
2	15 (9)
≥ 3	6 (4)
Previous medical therapy ^a	
None	35 (22)
Estrogen-progestins ^b	115 (73)
Progestins ^b	23 (15)
GnRH analogues	3 (2)
Dysmenorrhea	
NRS	9 (8-10); 8.6 ± 4.5
NRS > 5	148 (94)
Dyspareunia ^c	
NRS	6 (0-8); 5.1 ± 3.3
NRS > 5	85 (61)
Dyschezia	
NRS	2 (0-8); 3.7 ± 3.9
NRS > 5	65 (41)
Nonmenstrual pelvic pain	
NRS	5 (0-7); 3.9 ± 3.5
NRS > 5	67 (43)
No. of days per month with considerable pain ^d	6 (3-10)
No. of days per month with impairment of usual activity	2 (0-4)
SF-12 questionnaire	
Physical Component Summary Score	41.6 ± 10.8
Mental Component Summary Score	41.8 ± 10.6
FSFI total score ^c	26.4 ± 5.6

Note: Data are reported as mean ± standard deviation, n (%), or median (interquartile range). BMI = body mass index; FSFI = Female Sexual Function Index; GnRH = gonadotropin-releasing hormone; NRS = numeric rating scale (0-10); SF-12 = Short-form 12.

^a The sum does not add-up to the total because 17 women previously used more than one therapy.

^b Estrogen-progestins and progestins used previously were different from those used in the present study or were used with a different modality.

NRS = 0-10-point Numeric Rating Scale.

^c Refers to 140 women because 17 did not have sexual intercourses at study entry.

^d Pain necessitating analgesics.

Table 2. Per-protocol analysis of pain symptoms, health-related quality of life and sexual functioning scores variation between baseline and 12-month evaluation ($n = 133$).

Symptom/Questionnaire	Baseline	12-mo follow-up	<i>P</i> value
Dysmenorrhea			
NRS	8 (8-10); 8.6 ± 4.8	0 (0-0); 1.2 ± 2.6	<.001
NRS > 5	125 (94)	16 (12)	<.001
Dyspareunia ^a			
NRS	6 (0-8); 4.9 ± 3.4	0 (0-6); 2.6 ± 3.3	<.001
NRS > 5	70 (59)	35 (30)	<.001
Dyschezia			
NRS	4 (0-8); 3.8 ± 3.9	0 (0-0); 1.2 ± 2.6	<.001
NRS > 5	57 (43)	16 (12)	<.001
Nonmenstrual pelvic pain			
NRS	5 (0-7); 3.9 ± 3.6	0 (0-5); 2.5 ± 3.1	<.001
NRS > 5	58 (44)	31 (23)	<.001
No. of days per month with considerable pain ^b	7 (4-10)	0 (0-2)	<.001
No. of days per month with impairment of usual activity	2 (0-4)	0 (0-0)	<.001
SF-12 questionnaire			
Physical Component Summary Score	41.4 ± 11.1	51.0 ± 8.7	<.001
Mental Component Summary Score	41.9 ± 10.5	47.0 ± 10.0	<.001
FSFI total score ^a	26.4 ± 5.6	25.3 ± 6.1	.07

Note: Data are reported as median (interquartile range), mean ± standard deviation, or n (%). Women who withdrew ($n = 21$) or underwent surgery ($n = 3$) before 12 month follow-up assessment were excluded. FSFI = Female Sexual Function Index; NRS = numeric rating scale (0-10); SF-12 = Short Form 12.

^a Fifteen women did not have sexual activity either at baseline or at the pre-planned follow-up evaluations.

^b Pain necessitating analgesics.

778

779

780

781

782

783


784

785

Table 3. Side-effects in estrogen-progestins and progestins users during the study period.

Side-effect	3 mo (n = 151)	6 mo (n = 142)	12 mo (n = 133)
None	28 (18)	29 (20)	27 (20)
Headache	31 (20)	27 (19)	23 (17)
Spotting	55 (36)	36 (25)	30 (22)
Weight gain	43 (28)	44 (31)	46 (34)
Decreased libido	53 (35)	51 (36)	47 (35)
Vaginal Dryness	37 (24)	35 (25)	34 (25)
Mood disorders	23 (15)	22 (15)	20 (15)
Breast tenderness	16 (10)	12 (8)	11 (8)
Water retention	6 (4)	4 (3)	4 (3)
Acne	5 (3)	5 (3)	5 (4)
Others	10 (7)	8 (6)	10 (7)
Weight increase (Kg), mean ± SD	2.7 ± 0.5	2.0 ± 0.9	3.1 ± 1.2

786



787

788

789

790

Supplemental Table 1. Baseline ultrasonographic characteristics of study patients as assessed at transvaginal and/or transrectal examination.

Ultrasound findings	Participants (<i>n</i> = 157)
Ovarian endometriomas	
Absent	93 (59%)
Unilateral	51 (33%)
Bilateral	13 (8%)
Largest cyst diameter (mm)	26 [19-38]
Deep invasive endometriosis	
Absent	93 (59%)
Rectovaginal	56 (36%)
Other localizations	8 (5%)
Largest lesion diameter (mm)	15 [10-20]
Adenomyosis	33 (21%)

Data is reported as number (percentage), or median [interquartile range].

791

792

793

794

795

796

797

Supplemental Table 2. Comparison of baseline demographic and clinical characteristics of women who were or were not satisfied at 12-month follow-up evaluation ($n = 152$)^a.

Characteristic	Satisfied ($n = 95$)	Not satisfied ^b ($n = 57$)	<i>P</i>
Age (years)	32.9 ± 6.0	32.8 ± 5.5	0.94
Age at first diagnosis (years)	27.4 ± 5.2	27.0 ± 5.5	0.67
BMI (kg/m ²)	21.1 ± 3.2	22.4 ± 3.8	0.03
Previous deliveries	23 (24%)	11 (19%)	0.55
Previous interventions for endometriosis	45 (47%)	32 (56%)	0.32
Lesions detected at transvaginal and/or transrectal ultrasonography			
Deep invasive endometriosis	39 (41%)	24 (42%)	1.00
Endometriomas	37 (39%)	23 (40%)	0.87
Adenomyosis	24 (25%)	8 (14%)	0.15
Pain symptoms (NRS > 5)			
Dysmenorrhea	88 (93%)	56 (98%)	0.26
Dyspareunia	48 (56%) ^c	36 (72%) ^d	0.10
Dyschezia	40 (42%)	24 (42%)	1.00
Non-menstrual pelvic pain	38 (40%)	28 (49%)	0.31
No. of days per month with considerable pain ^c	6 [3-10]	7 [3-15]	0.20
No. of days per month with impairment of usual activity	2 [0-4]	2 [1-5]	0.20
SF-12 questionnaire			
Physical Component Summary Score	41.8 ± 11.2	41.2 ± 10.4	0.71
Mental Component Summary Score	43.0 ± 10.1	39.5 ± 11.4	0.048
FSFI total score	26.3 ± 5.3 ^c	26.4 ± 6.3 ^d	0.92